Zevtera / Mabelio (ceftobiprole)

Hospital- and community-acquired pneumonia

Phase

Marketed
Partnering status

Partnered
Partner

Correvio for Europe (excl. Nordics) and Israel; Unimedic for Nordics; Hikma for MENA region, Grupo Biotoscana for Latin America; Avir for Canada, CR Gosun for China
Available in

Major European and several international markets

You may also be interested in

Infectious diseases Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.

GI disorders Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database. Today, our development efforts are focused on non-viral diseases where cylophilins play a key role in regulating cell death pathways and we strive to generate compelling evidence supporting further clinical investigations in patients with high unmet medical needs.

Infectious diseases Debio 1561 FibroTrap is a unique sample preparation technology for the concentration of bacteria and other microorganisms in blood samples of patients with bloodstream infections (BSI). The technology will enable faster identification and diagnosis of pathogens directly from patient samples and will promote an accelerated selection of more appropriate antibiotics to improve treatment outcomes (antibiotics stewardship).